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bjectives The aim of this study was to evaluate outcomes of patients with moderate- and high-
isk acute coronary syndromes (ACS) and multivessel coronary artery disease managed with percuta-
eous coronary intervention (PCI) versus coronary artery bypass grafting (CABG).
ackground There is uncertainty about the preferred revascularization strategy for high-risk pa-
ients with multivessel disease.
ethods Among 13,819 moderate- and high-risk ACS patients enrolled in the ACUITY (Acute Cathe-
erization and Urgent Intervention Triage Strategy) trial, 5,627 had multivessel disease (including left an-
erior descending artery involvement) and were managed by PCI (n  4,412) or CABG (n  1,215). Pro-
ensity score matching was applied to adjust for differences in baseline clinical and angiographic
haracteristics, yielding a total of 1,056 patients (528 managed by PCI, and 528 managed by CABG).
esults Propensity-matched patients undergoing CABG had higher 1-month rates of stroke (1.1%
s. 0.0%, p  0.03) and myocardial infarction (13.3% vs. 8.8%, p  0.03), received more blood trans-
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oth 1 month and at 1 year (0.8% vs. 5.2%, p  0.0001; and 3.8% vs. 16.5%, p  0.0001, respec-
ively). There were no signiﬁcant differences between the CABG and PCI groups in 1-month or
-year mortality (2.5% vs. 2.1%, p  0.69; and 4.4% vs. 5.7%, p  0.58, respectively).
onclusions In this propensity-matched comparison from the ACUITY trial, moderate- and high-risk
atients with ACS and multivessel disease treated with PCI rather than CABG had lower rates of
eri-procedural stroke, myocardial infarction, major bleeding, and renal injury, with comparable
-month and 1-year rates of mortality, but more frequently developed recurrent ischemia requiring
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1060n early invasive approach in patients with moderate- and
igh-risk acute coronary syndromes (ACS) (1) is recom-
ended by the American Heart Association, the American
ollege of Cardiology, and the European Society of Cardiol-
gy (2–4). Although more than 1.4 million persons are
dmitted to hospitals in the U.S. every year with ACS (5),
elatively few studies have evaluated the optimal revascularization
odality for such patients. Most prior studies have been modest in
ize and have reported comparable outcomes in patients with
CS treated with either percutaneous coronary intervention
PCI) or coronary artery bypass graft surgery (CABG) (6).
owever, no recent studies have examined the contemporary
utcomes of PCI or CABG in these high-risk patients.
Therefore we evaluated the outcomes of patients with
moderate- and high-risk ACS
and multivessel disease undergo-
ing an early invasive manage-
ment strategy according to re-
vascularization modality from the
large-scale randomized ACUITY
(Acute Catheterization and Ur-
gent Intervention Triage Strat-
egy) trial.
Methods
Patients and study protocol. The
ACUITY trial (7) was a pro-
spective open-label randomized
multicenter trial that compared
3 different antithrombotic regi-
mens for patients presenting
with moderate- and high-risk
ACS and treated with an early
invasive management strategy.
Clinical follow-up at 450 aca-
demic and community-based in-
stitutions in 17 countries was
performed to determine 1-year
outcomes for these patients. The
tudy design and protocol as well as its principal results have
een described previously in detail (7). In brief, 13,819
atients presenting in non–ST-segment elevation ACS
ere randomized to receive unfractionated heparin or enox-
parin with a glycoprotein (GP) IIb/IIIa inhibitor, bivaliru-
in plus a GP IIb/IIIa inhibitor, or bivalirudin alone. Per
rotocol, angiography was required in all patients within
2 h of randomization with subsequent triage to PCI,
ABG, or medical management according to investigator
iscretion.
Inclusion criteria were patients 18 years of age or older
ith symptoms of ACS lasting 10 min within the pre-
eding 24 h with 1 or more of the following criteria: new
bbreviations
nd Acronyms
CS  acute coronary
yndrome(s)
MS  bare-metal stent(s)
ABG  coronary artery
ypass grafting
I  confidence interval
PK-MB  creatine
hosphokinase-myocardial
and
ES  drug-eluting stent(s)
P  glycoprotein
AD  left anterior
escending
ACE  major adverse
ardiovascular events
I  myocardial infarction
R  odds ratio
CI  percutaneous
oronary intervention
CA  quantitative coronary
ngiographyT-segment depression or transient elevation 1 mm; Plevated troponin I, troponin T, or creatine kinase-
yocardial band; known coronary artery disease; or the
resence of all 4 other Thrombolysis In Myocardial Infarc-
ion risk criteria (7). Exclusion criteria included acute
T-segment elevation myocardial infarction (MI) or shock;
leeding diathesis or major bleeding within 2 weeks; throm-
ocytopenia; creatinine clearance 30 ml/min; or recent
dministration of abciximab, warfarin, fondaparinux, fi-
rinolytic agents, bivalirudin, or 1 dose of low-molecular-
eight heparin. The study was approved by institutional
eview boards or ethics committees at each center, and all
atients provided written informed consent.
Aspirin was administered daily during the hospital stay
300 to 325 mg orally or 250 to 500 mg IV) and daily
ndefinitely in all patients after hospital discharge (75 mg).
lthough timing and initial dosing of clopidogrel were left
o the discretion of the investigator, a loading dose of 300
g or more was required within 2 h after PCI in all cases.
5-day clopidogrel washout period was recommended
efore surgery for patients who received clopidogrel and in
hom CABG was subsequently planned. Clopidogrel (75
g daily) was recommended for 1 year in all patients
ndergoing PCI and at operator discretion in patients
ndergoing CABG. All patients were anticoagulated during
ABG with unfractionated heparin, with dosing per standard
nstitutional practice.
nd points, deﬁnitions, and statistical analyses. Pre-
pecified major adverse cardiovascular events (MACE) were
ssessed at 1 month (end of the follow-up window 35 days)
nd 1 year (end of the follow-up window 395 days) after the
rocedure, consisting of all-cause death, MI, or unplanned
evascularization for recurrent ischemia, and were adjudi-
ated by a blinded Clinical Events Committee. An MI af-
er PCI was diagnosed if any creatine phosphokinase-
yocardial band (CPK-MB) was increased to 3 normal
ithin 24 h after the procedure or 1 normal with the
ccurrence of new, significant (0.04 s) Q waves in 2
ontiguous electrocardiographic leads. An MI after CABG
as diagnosed if any CPK-MB was increased to 10
ormal within 24 h after the procedure or to 5 normal
ith the occurrence of new, significant Q waves in 2
ontiguous electrocardiographic leads. Criteria were ad-
usted if the CPK-MB was not normal before the procedure
7). Major bleeding was defined as intracranial or intraoc-
lar bleeding; access site hemorrhage requiring intervention;
5-cm diameter hematoma; reduction in hemoglobin of
4 g/dl without or 3 g/dl with an overt bleeding source;
eoperation for bleeding; or blood product transfusion. The
etailed definitions for the other components of MACE
ave been previously detailed (7).
For the present study we compared the outcomes of
atients with multivessel coronary artery disease involving
he left anterior descending (LAD) artery who underwent
CI or CABG. The ACUITY core laboratory performed
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1061uantitative coronary angiography (QCA) on all lesions in
he coronary tree from 6,921 patients in a formal angio-
raphic substudy (8). A diseased epicardial vessel was
efined as a major vessel (LAD, left circumflex, or right
oronary artery, including its branches) containing 1 or
ore lesions with a diameter stenosis by QCA of 30%
roughly equivalent to a diameter stenosis of50% by visual
stimation). In patients without QCA, a diseased epicardial
oronary artery was defined by the investigator as a major
oronary vessel containing 1 or more lesions with a visually
stimated diameter stenosis of 50%. Multivessel disease
as then defined as 2 or more diseased epicardial coronary
rteries.
We further performed—due to substantial differences between
he groups (Table 1)—a propensity score analysis that was
atched for the following patient characteristics: age, sex,
iabetes, hypertension, hyperlipidemia, previous MI, previ-
us percutaneous transluminal coronary angioplasty, previ-
us CABG, renal insufficiency, elevated cardiac biomarkers,
T-segment deviation 1 mm, Thrombolysis In Myocar-
ial Infarction risk score, weight, left main disease, number
f diseased vessels, and left ventricular ejection fraction. The
robability (propensity score) that a patient would receive a
Table 1. Baseline Clinical and Angiographic Characte
Age (yrs)
Male
Weight (kg)
Diabetes
Insulin-requiring
Hypertension
Hyperlipidemia
Current smoker
Previous MI
Previous PCI
Previous CABG
Renal insufﬁciency
Baseline cardiac biomarker elevation or ST-segment deviatio
Baseline cardiac biomarker elevation
Baseline troponin elevation
ST-segment deviation 1 mm
TIMI risk score
Low (0–2)
Intermediate (3–4)
High (5–7)
Number of diseased vessels
LM disease
LAD disease
LCX disease
RCA disease
Left ventricular ejection fraction (%)
CABG  coronary artery bypass grafting; LAD  left anterior descePCI percutaneous coronary intervention; RCA right coronary artery; TIMICI or undergo CABG, according to the pre-procedural
ariables, was determined with a saturated logistic regres-
ion model to take into account the different patient profiles.
atients from the PCI group were then matched with
atients from the CABG group according to their propen-
ity score, resulting in 528 pairs of propensity-matched
atients (n  1,056 total) in whom early and late outcomes
ere determined. The C-statistic for the logistic regression
odel that was used to calculate the propensity score
atching for the 2 groups was 0.846.
Categorical variables were compared by chi-square or
isher exact test. Continuous variables were compared by
he nonparametric Wilcoxon rank sum test. Time-to-event
ata are displayed with Kaplan-Meier methodology and
ere compared with the log rank test.
esults
mong 13,819 moderate- and high-risk ACS patients
nrolled in the ACUITY trial between August 2003 and
ecember 2005 who underwent early angiographic assess-
ent, a total of 7,789 (56%) were managed by PCI and
,539 (11%) were managed by CABG. Among these, 5,627
s of Study Cohort
CABG (n  1,215) PCI (n  4,412) p Value
64.3 10.2 63.8 11.4 0.18
78.5% (954/1,215) 74.3% (3,280/4,412) 0.003
84.8 17.6 86.5 17.9 0.004
35.1% (423/1,206) 30.8% (1,349/4,382) 0.005
11.5% (139/1,206) 9.6% (419/4,382) 0.051
66.4% (806/1,214) 70.1% (3,078/4,389) 0.01
50.5% (595/1,178) 60.5% (2,626/4,341) 0.0001
28.0% (335/1,197) 28.3% (1,227/4,342) 0.88
24.6% (294/1,194) 35.3% (1,515/4,293) 0.0001
20.6% (248/1,203) 43.0% (1,876/4,363) 0.0001
4.7% (57/1,214) 25.2% (1,110/4,401) 0.0001
18.5% (210/1,137) 20.3% (844/4,160) 0.18
87.1% (1,018/1,169) 74.0% (3,132/4,230) 0.0001
74.6% (850/1,140) 63.0% (2,610/4,142) 0.0001
71.8% (786/1,094) 62.1% (2,414/3,888) 0.0001
50.8% (617/1,215) 35.2% (1,551/4,409) 0.0001
10.9% (120/1,099) 12.6% (486/3,857) 0.14
54.3% (597/1,099) 52.0% (2,004/3,857) 0.17
34.8% (382/1,099) 35.4% (1,367/3,857) 0.69
2.64 0.60 2.07 0.76 0.0001
28.1% (341/1,215) 5.6% (248/4,412) 0.0001
100.0% (1,215/1,215) 100.0% (4,412/4,412) 1.00
88.6% (1,077/1,215) 77.2% (3,408/4,412) 0.0001
88.7% (1,078/1,215) 81.1% (3,576/4,412) 0.0001
52.0 13.3 53.4 12.8 0.004
LCX  left circumflex; LM  left main; MI  myocardial infarction;ristic
n
nding; Thrombolysis In Myocardial Infarction.
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1062atients had multivessel coronary artery disease involving
he LAD territory, with 4,412 and 1,215 patients treated
ith PCI and CABG, respectively. Baseline and angio-
raphic characteristics of these patients varied significantly
etween the groups and are displayed in Table 1. Specifi-
ally, patients undergoing CABG compared with PCI were
ore often female and more likely to have diabetes, cardiac
iomarker elevation, or ST-segment deviation, more exten-
ive coronary artery disease (including left main disease),
nd a lower left ventricular ejection fraction. In contrast,
atients undergoing PCI were heavier and more likely to
ave hypertension; hyperlipidemia; and prior MI, PCI, or
ABG.
esults before propensity matching. Early (1-month) and
ate (1-year) unadjusted clinical outcomes of the study
atients are shown in Table 2. Patients undergoing CABG
ompared with PCI had significantly higher unadjusted
arly rates of mortality (3.4% vs. 1.4%, p  0.0001), stroke,
I, major bleeding, and acute renal injury and higher late (1
Table 2. Early and Late Clinical Outcomes Before Ma
1-month outcomes
MACE
Death
Cardiac death
MI
Unplanned revascularization for ischemia
PCI
CABG
Unplanned target vessel revascularization for ischemia
Unplanned target lesion revascularization for ischemia
Stroke
Transient ischemic attack
Bleeding events
Blood transfusions
Acute renal injury*
1-yr outcomes
MACE
Death
Cardiac death
MI
Unplanned revascularization for ischemia
PCI
CABG
Unplanned target vessel revascularization for ischemia
Unplanned target lesion revascularization for ischemia
Stroke
Transient ischemic attack
n5,627. Rates aredisplayedasKaplan-Meier percentageestimates (n
Triage Strategy) scale definition for bleeding events (major): reoperat
overt source of bleeding (or 4 g/dl without); use of any blood pro
requiring intervention; 5-cm diameter hematoma. *Relative 25% in
compared with baseline.MACEmajor adverse cardiovascular events; other abbreviations as in Tabear) rates of death (5.7% vs. 4.1%, p  0.002). Although
epeat revascularization for ischemia was less common with
ABG at both time periods by multivariable analysis
ithout propensity score matching, 1-month and 1-year
ortality were not significantly different according to revas-
ularization modality (odds ratio [OR]: 1.52, 95% confi-
ence interval [CI]: 0.91 to 2.53, p  0.11; OR: 1.01, 95%
I: 0.68 to 1.50, p  0.96 for CABG vs. PCI, at 1-month
nd 1-year, respectively). Coronary artery bypass grafting
as, however, associated with a significant increase in the
ate of early and late MI (OR: 3.01, 95% CI: 2.31, 3.93, p
.0001; OR: 2.06, 95% CI: 1.60 to 2.63, p  0.0001,
espectively). Conversely, CABG was associated with lower
-month and 1-year rates of unplanned repeat revascular-
zation for ischemia (OR: 0.38, 95% CI: 0.22 to 0.65, p 
.0005; OR: 0.48, 95% CI: 0.35 to 0.65, p  0.0001,
espectively).
esults after propensity matching. The baseline clinical and
ngiographic characteristics of the 2 propensity-matched
g
ABG (n  1,215) PCI (n  4,412) p Value
14.3% (173) 10.4% (457) 0.0003
3.4% (41) 1.4% (60) 0.0001
3.2% (39) 1.2% (53) 0.0001
11.5% (138) 7.1% (310) 0.0001
1.2% (15) 4.2% (185) 0.0001
0.8% (10) 3.4% (147) 0.0001
0.4% (5) 1.0% (45) 0.046
0.3% (3) 2.5% (111) 0.0001
0.2% (2) 1.9% (84) 0.0001
0.9% (11) 0.2% (10) 0.002
0.2% (3) 0.1% (3) 0.12
54.0% (654) 7.5% (329) 0.0001
40.8% (493) 4.1% (181) 0.0001
31.5% (337) 12.2% (469) 0.0001
19.1% (230) 22.9% (962) 0.056
5.7% (68) 4.1% (160) 0.002
3.9% (47) 2.4% (103) 0.003
12.0% (144) 10.5% (448) 0.08
4.2% (49) 15.0% (624) 0.0001
3.7% (43) 12.8% (531) 0.0001
0.6% (7) 2.6% (112) 0.0001
0.3% (4) 10.2% (423) 0.0001
0.3% (3) 8.7% (359) 0.0001
1.0% (12) 0.2% (10) 0.0007
0.2% (3) 0.1% (3) 0.12
f events). TheACUITY (AcuteCatheterizationandUrgent Intervention
leeding, reduction in hemoglobin concentration of3 g/dl with an
ansfusion; intracranial/intraocular bleeding; access site hemorrhage
or absolute 0.5-mg/dl increase in serum creatinine after proceduretchin
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1063roups (528 pairs, n  1,056 total) were balanced in all
easured characteristics (Table 3). Among PCI-treated
atients, stents were implanted in 92.8% of all patients, with
rug-eluting stents (DES) used in 61.8% of stented pa-
ients. Mean number of vessels and lesions treated in the
CI group were 1.36  0.59 and 1.83  1.13, respectively.
n the CABG group, the mean number of grafts/patient was
.37  1.07, and 13.1% of the patients were operated
ithout use of cardiopulmonary bypass (off-pump CABG).
The mean duration of hospital stay was 13.0  18.1 days
or the CABG group versus 5.1  6.8 days for the PCI
roup (p  0.0001). This difference derived from a longer
ime both from admission to revascularization (5.6  17.0
ays vs. 1.2  1.6 days, p  0.0001) as well as from
evascularization to hospital discharge (8.2  7.6 days vs.
.0  6.6 days, p  0.0001) in the CABG compared with
he PCI group.
The early and late clinical outcomes of the propensity-
atched groups of patients are shown in Table 4. At
-month there was no significant difference in all-cause
ortality (2.5% for CABG vs. 2.1% for PCI, p  0.69),
ardiac mortality, or MACE in patients managed with
ABG versus PCI. The rates of MI, stroke, major bleeding,
Table 3. Baseline and Angiographic Characteristics A
Age (yrs)
Male
Weight (kg)
Diabetes
Insulin-requiring
Hypertension
Hyperlipidemia
Current smoker
Previous MI
Previous PCI
Previous CABG
Renal insufﬁciency
Baseline cardiac biomarker elevation or ST-segment deviatio
Baseline cardiac biomarker elevation
Baseline troponin elevation
ST-segment deviation 1 mm
TIMI risk score
Low (0–2)
Intermediate (3–4)
High (5–7)
Number of diseased vessels
LM disease
LAD disease
LCX disease
RCA disease
Left ventricular ejection fraction
n 1,056.Abbreviations as in Tables 1 and 2.nd acute renal injury at 1-month were higher in the CABG
roup; however, the rate of unplanned repeat revasculariza-
ion for ischemia was higher in the PCI group. At 1 year the
ropensity-adjusted rates of total mortality (4.4% for
ABG vs. 5.7% for PCI, p  0.58) as well as for cardiac
ortality did not differ between the 2 groups (Fig. 1). The
-year rate of MI was no longer significantly different
etween the 2 groups. The rate of unplanned repeat
evascularization remained significantly higher in the PCI
roup at 1 year, however. As a result of the increased rate of
epeat revascularization, a strong trend was present for a
reater rate of MACE at 1 year with PCI compared with
ABG. There were no additional strokes after 30 days in
he present study in either propensity-matched group. The
utcomes of the multivariable analysis and propensity score
nalysis are provided in Figures 2 and 3, respectively.
iscussion
he major findings of the present study—in which
ropensity score modeling from a large, contemporary,
ulticenter, prospective randomized trial was used to
ssess the comparative outcomes of PCI and CABG in
ropensity Matching
CABG (n  528) PCI (n  528) p Value
63.9 10.3 64.0 11.6 0.83
77.8% (411/528) 77.1% (407/528) 0.83
84.9 18.2 (528) 84.7 17.3 (528) 0.90
31.8% (168/528) 32.8% (173/528) 0.79
10.6% (56/528) 8.9% (47/528) 0.41
66.1% (349/528) 65.3% (345/528) 0.85
50.8% (268/528) 50.9% (269/528) 1.00
26.8% (140/523) 30.3% (158/521) 0.22
25.0% (132/528) 25.2% (133/528) 1.00
24.6% (130/528) 23.5% (124/528) 0.72
6.3% (33/528) 8.1% (43/528) 0.28
17.0% (90/528) 18.4% (97/528) 0.63
85.6% (452/528) 85.8% (453/528) 1.00
73.5% (388/528) 73.5% (388/528) 1.00
70.8% (364/514) 72.4% (364/503) 0.63
48.5% (256/528) 51.1% (270/528) 0.42
12.3% (65/528) 10.8% (57/528) 0.51
55.1% (291/528) 54.9% (290/528) 1.00
32.6% (172/528) 34.3% (181/528) 0.60
2.61 0.64 (528) 2.61 0.60 (528) 0.92
9.3% (49/528) 10.6% (56/528) 0.54
100.0% (528/528) 100.0% (528/528) 1.00
83.9% (443/528) 82.6% (436/528) 0.62
81.8% (432/528) 85.6% (452/528) 0.11
53.1% 13.1 (528) 53.1% 12.9 (528) 0.99fter P
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1064atients with ACS and multivessel disease undergoing an
arly invasive strategy—are that selection of either revas-
ularization procedure may be performed with compara-
le rates of survival at both 1 month and 1 year. However,
he safety and efficacy profiles of PCI and CABG vary
ubstantially, with PCI associated with lower rates of
eri-procedural stroke, MI, major bleeding, and acute renal
njury, whereas CABG is associated with greater freedom
rom both early and late recurrent ischemia requiring repeat
evascularization procedures.
Selection of the optimal revascularization modality for
atients with multivessel disease continues to be controver-
ial. This is especially true in patients with ACS, because
ost prior comparative studies of CABG and PCI have
nrolled mostly patients with stable ischemic heart disease
6). The safety and utility of CABG in patients with
Table 4. Early and Late Clinical Outcomes After Prop
1-month outcomes
MACE
Death
Cardiac death
MI
Unplanned revascularization for ischemia
PCI
CABG
Unplanned target vessel revascularization for ischemia
Unplanned target lesion revascularization for ischemia
Stroke
Transient ischemic attack
Bleeding events
Blood transfusions
Acute renal injury*
1-yr outcomes
MACE
Death
Cardiac death
Bleeding related death
Unknown cause
MI
Unplanned revascularization for ischemia
PCI
CABG
Unplanned target vessel revascularization for ischemia
Unplanned target lesion revascularization for ischemia
Stroke
Transient ischemic attack
n  1,056. Rates are displayed as Kaplan-Meier percentage estimat
reoperation for bleeding; reduction in hemoglobin concentration of
product transfusion; intracranial/intraocular bleeding; access site hem
increase or absolute 0.5-mg/dl increase in serum creatinine after proce
Abbreviations as in Tables 1, 2, and 3.ultivessel disease and ACS are well-established (9–11). pecent studies have also demonstrated that PCI may be
afely performed in patients with multivessel disease with
utcomes comparable to those expected in patients with
ingle vessel disease, even in the setting of ACS (12–14). By
educing restenosis, DES have further improved the rates of
vent-free survival in patients with ACS undergoing PCI.
n the TAXUS IV-SR (Treatment of De Novo Coronary
isease Using a Single Paclitaxel-Eluting Stent) trial,
mong 450 patients presenting with ACS, treatment with
aclitaxel-eluting stents resulted in a 1-year target vessel
evascularization rate of 3.9% compared with 16.0% in those
atients treated with bare-metal stents (BMS) (15). A
ecent report from the Massachusetts State database in
atched ACS patients undergoing PCI with DES com-
ared with BMS demonstrated significantly lower 2-year
umulative rates of death, MI, or repeat revascularization
Matching
CABG (n  528) PCI (n  528) p Value
14.8% (78) 12.2% (64) 0.25
2.5% (13) 2.1% (11) 0.69
2.3% (12) 2.1% (11) 0.85
13.3% (70) 8.8% (46) 0.03
0.8% (4) 5.2% (27) 0.0001
0.6% (3) 3.7% (19) 0.0005
0.2% (1) 1.9% (10) 0.006
0.2% (1) 3.1% (16) 0.0002
0.2% (1) 2.1% (11) 0.004
1.1% (6) 0.0% (0) 0.03
0.0% (0) 0.2% (1) 1.00
45.5% (240) 9.1% (48) 0.0001
40.3% (212) 6.3% (33) 0.0001
31.7% (158) 14.2% (70) 0.0001
19.2% (101) 25.0% (129) 0.053
4.4% (23) 5.7% (27) 0.58
3.1% (16) 4.7% (23) 0.26
0.2% (1) 0.0% (0) 0.32
0.0% (0) 0.2% (1) 0.32
13.9% (73) 11.3% (59) 0.22
3.8% (19) 16.5% (83) 0.0001
3.6% (18) 13.1% (66) 0.0001
0.4% (2) 4.0% (20) 0.0001
0.2% (1) 12.0% (60) 0.0001
0.2% (1) 10.9% (54) 0.0001
1.1% (6) 0.0% (0) 0.03
0.0% (0) 0.2% (1) 1.00
f events). The ACUITY scale definition for bleeding events (major):
ith an overt source of bleeding (or4 g/dl without); use of any blood
e requiring intervention; 5-cm diameter hematoma. *Relative 25%
mpared with baseline.ensity
es (n o
3 g/dl w
orrhag
dure corocedures for patients treated with DES (16).
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1065Limited randomized trial data (none of which are con-
emporary) are available to guide selection of the appropri-
te revascularization strategy for high-risk ACS patients
ith multivessel disease. A pooled analysis from 10 ran-
omized trials (6) reported no significant difference in
ortality among 2,653 patients with multivessel disease and
CS treated by CABG versus PCI (with balloon angio-
lasty or BMS only) after a median follow-up of 5.9 years
9.6% vs. 11.1%, respectively; hazard ratio: 0.95, 95% CI:
.80 to 1.12).
None of the aforementioned trials used DES, let alone
he routine use of contemporary adjunct pharmacologic
herapies recommended in patients with ACS such as
Figure 1. 1-Year Outcomes (%) for Propensity-Matched PCI and CABG Pati
CABG  coronary artery bypass grafting; CVA  cerebrovascular accident; MA
ous coronary intervention.
Figure 2. Forest Plot With Early (30-Day) and Late (1-Year) Outcomes of MCI  conﬁdence interval; OR  odds ratio; other abbreviations as in Figure 1.hienopyridines, GP IIb/IIIa inhibitors, or direct thrombin
nhibitors. Surgical therapies and outcomes have also con-
inued to improve. Recently, the SYNTAX (Synergy Be-
ween PCI With Taxus and Cardiac Surgery) trial random-
zed 1,800 patients with triple vessel and/or left main
isease to paclitaxel-eluting stents and contemporary phar-
acotherapy versus CABG (17). With follow-up to 1 year,
CI and CABG resulted in nonsignificantly different rates
f death and MI. Fewer PCI patients had stroke (0.6% vs.
.2%, p  0.003), whereas despite the use of DES, fewer
ABG patients required repeat revascularization (13.5% vs.
.9%, p  0.001). However, only 28.5% of the patients in
he SYNTAX trial had unstable angina, an underpowered
major adverse cardiac events; MI  myocardial infarction; PCI  percutane-
riable Analysisents
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1066ubgroup for which the event rates have not separately been
eported.
In this regard, the results of the present study, represent-
ng a nonrandomized but propensity score-adjusted com-
arison of PCI versus CABG in 1,056 patients with
ultivessel disease and ACS, are for the most part consis-
ent with the SYNTAX trial findings. Coronary artery
ypass grafting compared with PCI (with DES used in
0.7% of patients) resulted in a higher incidence of major
leeding and peri-procedural stroke (as seen in most prior
tudies of CABG vs. PCI) (18), greater renal insufficiency
also consistent with some [19,20] but not all [21] prior
tudies), and a lower rate of early and late recurrent ischemia
ecessitating repeat revascularization procedures, with com-
arable mortality. The lower 1-month rate of MI observed
n the present study with PCI was not present in the
YNTAX trial or most earlier studies, however, and by 1
ear this difference was no longer significant.
tudy limitations. Several limitations of the present study
hould be noted. The ACUITY trial was not a randomized
rial of revascularization modalities in ACS, and even
ropensity score matching cannot correct for unmeasured
onfounders. Important covariates (mainly procedural) such
s vessel diameter, lesion length, and morphology were not
ncluded in the present analysis. These parameters, which
ffect restenosis, recurrent angina, and reintervention rates
mong patients undergoing PCI, are less important in the
urgical group (17). Detailed CABG data, including the
xact types of grafts used and vessels treated and complete-
Figure 3. Forest Plot With Early (30-Day) and Late (1-Year) Outcomes of P
Note that in the propensity-matched analysis there were no strokes in patient
risk; other abbreviations as in Figures 1 and 2.ess of revascularization, were incomplete. “Off-pump” tABG (infrequently used in the present series) has been
urported to reduce reperfusion injury and “no reflow” in
atients with ACS, thereby improving outcomes (22).
owever, a recent randomized trial reported reduced graft
atency and event-free survival with off-pump compared
ith on-pump CABG (23). The relative rates of MI after
CI versus CABG depend on the specific definitions used.
requently, different biomarker thresholds are employed for
he 2 revascularization modalities, as were pre-specified in
he ACUITY trial. Finally the follow-up period of 1 year
ight not be sufficient to evaluate the long-term effects of
CI versus CABG.
onclusions
he present large-scale, contemporary study confirms prior
eports demonstrating comparable 1-year survival and MI
ates with PCI and CABG in patients with multivessel
isease and ACS requiring revascularization. This finding
eaffirms the legitimacy of both percutaneous intervention
nd surgical revascularization in these high-risk patients.
eyond survival, offsetting considerations that might affect
he choice of PCI versus CABG include peri-procedural
omplications (particularly stroke, bleeding, renal injury,
nd a longer initial hospital stay) with CABG versus
educed long-term freedom from recurrent ischemia and
epeat revascularization procedures with PCI. However,
hese conclusions are based on the current data available
rom randomized and nonrandomized trials. Larger con-
sity Score Analysis
rgoing PCI. As such, stroke is not displayed in the Forest plots. RR  relativeropen
s undeemporary studies with longer-term follow-up are required
t
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1067o fully characterize the relative safety and efficacy profiles of
CI and CABG in patients with ACS.
eprint requests and correspondence: Dr. Gregg W. Stone,
olumbia University Medical Center, The Cardiovascular Re-
earch Foundation, 111 East 59th Street, 11th Floor, New York,
ew York 10022. E-mail: gs2184@columbia.edu.
EFERENCES
1. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive
strategies in patients with acute coronary syndromes: a collaborative
meta-analysis of randomized trials. JAMA 2005;293:2908–17.
2. Braunwald E, Antman EM, Beasley JW, et al. Management of patients
with unstable angina and non–ST-segment elevation myocardial in-
farction: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. Available at:
http://www.acc.org/qualityandscience/clinical/guidelines/unstable/unstable_
pkt.pdf. Accessed October 30, 2006.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline
update for the management of patients with unstable angina and
non-ST-segment elevation myocardial infarction—2002: summary ar-
ticle: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on the
Management of Patients With Unstable Angina). J Am Coll Cardiol
2002;40:1366–74.
4. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute
coronary syndromes in patients presenting without persistent ST-
segment elevation. Eur Heart J 2002;23:1809–40.
5. Graves EJ, Kozak LJ. Detailed diagnoses and procedures, National
Hospital Discharge Survey, 1996. Vital Health Stat 13 1998:i–iii,
1–151.
6. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass
surgery compared with percutaneous coronary interventions for mul-
tivessel disease: a collaborative analysis of individual patient data from
ten randomised trials. Lancet 2009;373:1190–7.
7. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with
acute coronary syndromes. N Engl J Med 2006;355:2203–16.
8. Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients
with acute coronary syndromes treated with drug-eluting and bare
metal stents: the Acute Catheterization and Urgent Intervention
Triage Strategy trial. Circulation 2009;119:687–98.
9. Solodky A, Behar S, Boyko V, Battler A, Hasdai D. The outcome of
coronary artery bypass grafting surgery among patients hospitalized
with acute coronary syndrome: the Euro Heart Survey of acute
coronary syndrome experience. Cardiology 2005;103:44–7. e0. Monteiro P. Impact of early coronary artery bypass graft in an
unselected acute coronary syndrome patient population. Circulation
2006;114 Suppl:I467–72.
1. Alexiou K, Kappert U, Staroske A, et al. Coronary surgery for acute
coronary syndrome: which determinants of outcome remain? Clin Res
Cardiol 2008;97:601–8.
2. Chen LY, Lennon RJ, Grantham JA, et al. In-hospital and long-term
outcomes of multivessel percutaneous coronary revascularization after
acute myocardial infarction. Am J Cardiol 2005;95:349–54.
3. Shishehbor MH, Lauer MS, Singh IM, et al. In unstable angina or
non-ST-segment acute coronary syndrome, should patients with mul-
tivessel coronary artery disease undergo multivessel or culprit-only
stenting? J Am Coll Cardiol 2007;49:849–54.
4. Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos
LA, Cannon CP. Efficacy and safety of multivessel percutaneous
revascularization and tirofiban therapy in patients with acute coronary
syndromes. Am J Cardiol 2002;90:631–3.
5. Moses JW, Mehran R, Nikolsky E, et al. Outcomes with the paclitaxel-
eluting stent in patients with acute coronary syndromes: analysis from
the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1165–71.
6. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents
for acute myocardial infarction. N Engl J Med 2008;359:1330–42.
7. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
intervention versus coronary-artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961–72.
8. Bravata DM, Gienger AL, McDonald KM, et al. Systematic review: the
comparative effectiveness of percutaneous coronary interventions and
coronary artery bypass graft surgery. Ann Intern Med 2007;147:703–16.
9. Mack MJ, Brown PP, Kugelmass AD, et al. Current status and
outcomes of coronary revascularization 1999 to 2002: 148,396 surgical
and percutaneous procedures. Ann Thorac Surg 2004;77:761–8.
0. Mack MJ, Prince SL, Herbert M, et al. Current clinical outcomes of
percutaneous coronary intervention and coronary artery bypass grafting.
Ann Thorac Surg 2008;86:496–503.
1. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with
chronic renal insufficiency in the Bypass Angioplasty Revascularization
Investigation. Circulation 2002;105:2253–8.
2. Rastan AJ, Eckenstein JI, Hentschel B, et al. Emergency coronary
artery bypass graft surgery for acute coronary syndrome: beating heart
versus conventional cardioplegic cardiac arrest strategies. Circulation
2006;114 Suppl:I477–85.
3. Shroyer AL, Grover FL, Hattler B, et al., Veterans Affairs Randomized
On/Off Bypass (ROOBY) Study Group. On-pump versus off-pump
coronary-artery bypass surgery. N Engl J Med 2009;361:1827–37.
ey Words: ACS  acute coronary syndrome  CABG 
oronary artery bypass grafting  multivessel coronary dis-
ase  PCI  percutaneous coronary intervention.
